Cerep and Servier Establish a new Collaboration Agreement for Drug Discovery and Lead Optimization
News Jun 18, 2009
Cerep announces the signature with Servier of a 3-year collaboration agreement for the discovery and optimization of new drugs. The terms of the agreement provide that Servier will identify targets of interest and will transfer to Cerep its collection of compounds.
Cerep will be responsible for the development and validation of the corresponding pharmacological assays and will run high throughput screenings on Servier library.
As part of this agreement, Cerep will also profile hit compounds identified during the high throughput screening campaigns as well as the drug candidates optimized for the selected target. Screening and profiling data will be made available in real time through the secured web access system Data OnLine developed by Cerep.
In addition, Servier will have access to BioPrint® services for an improved interpretation of in vitro data and for a better selection of drug candidates with less potential side effects and optimized safety profile.
Financial terms of the agreement are undisclosed; they include a monthly payment during the 3 years of the collaboration. Thierry Jean, Chairman and CEO of Cerep, commented: "Servier is an historical partner of Cerep and we have continuously entertained excellent relationships. We are particularly happy to sign a new collaboration which illustrates the high level of confidence and respect shared by the two companies."
Emmanuel Canet, President of Research and Development of Servier, declared: "With this agreement, Servier takes a new step in its contribution to medical progress and therapeutic innovation and confirms its commitment to collaborate with innovative biotech and research companies in France."
Bernard Marchand, Research Director at Servier, added: "With its experience in the development of new pharmacological assays, its organization and expertise in compound management and screening, but also the access to its BioPrint® database and tools, Cerep is a partner of choice for our new drug discovery research programs."
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
3-D Tissue Model of Developing Heart Could Aid Drug Safety Testing for Pregnant WomenNews
Parents and doctors often have to consider the mother's health as well as the potential risk regarding how medication could affect their baby. Researchers have developed a process to make a 3D tissue model that could mimic early stage human heart development, which could aid drug safety testing and help determine a drug's effects on fetal development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018